ABSTRACT: This article reviews the context and evidence of recent myocardial revascularization trials that compared percutaneous coronary intervention with coronary artery bypass grafting for the treatment of left main and multivessel coronary artery disease. We develop the rationale that some of the knowledge synthesis resulting from these trials, particularly with regard to the claimed noninferiority of percutaneous coronary intervention beyond nondiabetic patients with low anatomic complexity, may have been affected by trial design, patient selection based on suitability for percutaneous coronary intervention, and end point optimization favoring percutaneous coronary intervention over coronary artery bypass grafting. We provide recommendations that include holding a circumspect interpretation of the currently available evidence, as well as suggestions for the collaborative design and conduct of future clinical trials in this and other fields.
O
ver the past 2 decades, the question of whether percutaneous coronary intervention (PCI) is as effective a form of myocardial revascularization as coronary artery bypass grafting (CABG) for the treatment of left main (LM) and multivessel coronary artery disease (CAD) has been studied in more than a dozen sizable randomized controlled trials (RCTs). Nowadays, cardiologists and cardiac surgeons agree that PCI is a safe and effective modality for patients acutely presenting with ST-segment-elevation myocardial infarction (MI), patients with LM disease and low to intermediate anatomic complexity, and selected nondiabetic patients with multivessel CAD who have focal involvement and low anatomic complexity (Table 1) . At the other end of the spectrum, patients who have extensive or diffuse multivessel CAD, patients with LM disease and high anatomic complexity, and patients with diabetes mellitus and multivessel CAD are considered likely to fare better with CABG unless comorbidities are significant, surgical risk is high, or the potential for long-term survival is limited. Cardiologists and cardiac surgeons also generally agree that a separate discussion should take place after the diagnostic coronary angiography with patients who have stable CAD and who fall outside the above criteria. During this discussion, a heart team recommendation that takes into consideration not only the patient's characteristics and preferences but also the levels of expertise at the center should be provided to the patient, who can decide outside the constraints of an urgent setting.
Areas of major controversy also remain in the field of myocardial revascularization. From a technical perspective, interventional cardiologists and cardiac surgeons have a different view of what constitutes complete revascularization that is based on either functional (ie, PCI of vessels with an invasive fractional flow reserve of ≤0.80) 4 or anatomic (bypass of all coronary arteries with a diameter ≥1.5 mm and a luminal reduction of ≥50% in at least 1 angiographic view) criteria. 5 The use of PCI-based fractional flow reserve criteria has occasionally spread to CABG practice without evidence that reclassification of the revascularization strategy (ie, fractional flow reserve to help determine whether medical therapy, PCI, or CABG should be recommended) or the withholding of a bypass graft during CABG because of a fractional flow reserve value >0.80 is warranted, apart from considerations about graft patency and conduit selection (ie, whether an artery or vein graft should be used, according to competitive flow potential). Another area of controversy is whether complete revascularization after an acute MI, which has been found to result in benefit compared with a culprit-only strategy, 6 should be undertaken with PCI or CABG; moreover, the optimal timing of revascularization for nonculprit stenoses is not known. It also remains unclear whether the results of RCTs performed in patients with stable CAD, especially with regard to anatomic complexity and the presence of diabetes mellitus, should be applied to patients who recently had an MI. 7 Furthermore, RCTs comparing PCI with CABG have enrolled very few patients with systolic contractile dysfunction; whether medical therapy, PCI, or CABG represents the best intervention for those patients is another topic of debate.
However, above all, it is the interpretation of recent trials involving patients with LM and multivessel CAD such as NOBLE (Nordic-Baltic-British Left Main Revascularization), EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization), and a subsequently published patient-level meta-analysis [8] [9] [10] that continues to fuel controversy in the field of myocardial revascularization. These studies have suggested that PCI may be equivalent to CABG with regard to major adverse cardiovascular events (ie, MI, stroke, or cardiovascular death) and that, with the exception of diabetic patients with a high SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score, 10 there may be no particular subgroup of patients who benefit from CABG. 9, 10 Because no new major trial comparing PCI with CABG for LM or multivessel CAD is underway, these data are likely to represent, for many years, the latest information on this topic available to the cardiovascular community. We believe that issues related to trial design in some of the PCI versus CABG studies, including the selection of patients based on suitability for PCI, end point definitions for periprocedural MI that varied between and even within trials, and incorrect subgroup analysis practices, could have contributed to the overoptimized design and misinterpretation of these RCTs, with a potential to affect the recommendations provided in clinical guidelines. Understanding these pitfalls, which are described in this article, may help avoid repeating them in future myocardial revascularization trials and enhance the cardiovascular community's interpretation of the currently available evidence.
EQUIPOISE BY DESIGN FROM THE GROUND UP: IMPLICATIONS AT THE INDIVIDUAL PATIENT, TRIAL, META-ANALYSIS, AND GUIDELINES LEVELS
Most trials comparing PCI with CABG have not been designed and powered to individually address the po- tential inferiority of PCI with regard to freedom from major adverse cardiovascular events. Furthermore, with CABG as the recognized gold standard for patients with severe LM or multivessel CAD, clinicians and investigators have been hesitant to enroll patients in myocardial revascularization trials unless they were considered to be particularly suitable for PCI.
This issue of whether enrolled patients are typical of routine clinical practice was raised more than a decade ago. 11 It was noted then that the trials had enrolled fewer than 5% of the total potentially eligible population, usually those with modest CAD involvement. The generalization of results from those trials, which reported no difference in survival between PCI and CABG, to the larger population of patients with severe CAD, most of whom would not have been randomized in the context of a trial, may have contributed to an explosive growth in the use of PCI.
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A similar situation occurred in the recent NOBLE and EXCEL trials. For instance, the EXCEL trial completed enrollment with 729 (38%) fewer subjects than originally planned. 9 As in every myocardial revascularization trial that reported recruitment rates and the reasons for nonenrollment, the possibility of suboptimal outcomes with PCI was the predominant cause for nonenrollment, even beyond the screening phase. Similarly, in the SYNTAX trial, which aspired to represent a clinically realistic all-comers trial, of the >1000 patients deemed ineligible for randomization and entered into a parallel registry, the vast majority had been excluded from randomization because the complexity and severity of CAD made them unsuitable for PCI yet still suitable for CABG. 12 In the EXCEL trial, by the time 1000 patients were recruited to the companion registry (who in large part underwent CABG), only 747 patients had been randomized into the study. Notably, EXCEL had stipulated a SYNTAX score of <33 for inclusion. Even in those patients with less complex LM disease, the most frequent reasons for nonrandomization were that "PCI should not be performed" followed by "the presence of any clinical condition which leads the participating interventional cardiologist to believe that clinical equipoise is not present." 9 Fewer than one-third of patients in the EXCEL registry ultimately underwent PCI.
We believe that the repetitive practice of limiting trial enrollment to patients considered to be particularly suitable for PCI, anatomically and physiologically, amounts to a form of selection bias. Although this practice may be in the best interest of the study patients, the external validity and generalizability of myocardial revascularization trials suffer from having excluded subjects with less than optimal suitability for PCI (who may have experienced a less favorable outcome) and nevertheless applying the results of these RCTs to the whole population of patients with severe CAD.
Consequently, if PCI were deemed noninferior to CABG in individual myocardial revascularization trials or in the pooling of their data, would a conclusion that PCI be substituted for CABG in the real world be appropriate? Although RCTs always involve a select group of subjects, a context that emphasizes "noninferiority from the ground up," with systematic selection of patients because of suitability toward 1 of the 2 interventions, in every trial from which these data are available, may have resulted in bias at inception.
CHANGING DEFINITIONS OF END POINTS BETWEEN AND WITHIN TRIALS
There is abundant literature on the use of composite primary end points and their subcomponents in trials that have compared PCI with CABG for myocardial revascularization. 13 For instance, whether a stroke equates to an MI or alternatively amounts to an MI plus 1 target vessel revascularization episode has been a longstanding source of debate. Undoubtedly, composite primary end points are practical but also suboptimal.
14 Their post hoc splitting and pooling also can lead to methodological shortcomings, 13 as described in the next section.
Individual end point-related questions that are relevant to recent RCTs comparing PCI to CABG include the following: Does target vessel revascularization constitute a benign outcome, despite the paucity of dedicated literature examining its late effects? Should periprocedural MI, arbitrarily defined by enzyme release thresholds that vary from 1 trial to another using biochemical assays that also fluctuate from 1 laboratory to another, represent an important hypothesized clinical outcome difference between PCI and CABG? [15] [16] [17] [18] On these issues, the latest 2 trials, NOBLE and EX-CEL, took opposite approaches. NOBLE, like previous trials, included target vessel revascularization as part of its composite primary end point, whereas EXCEL did not. 8, 9 Furthermore, NOBLE did not consider periprocedural MI to be an important and comparable source of clinical difference and did not include it in its composite primary end point. What happened in this regard in the EXCEL trial is noteworthy.
The EXCEL trial was published in December 2016. 9 We observed previously that the noninferiority result in EXCEL was enabled by the definition of periprocedural MI, 19 which changed during the course of the trial. The final definition, used for the primary end point of the trial, was developed near the end of its recruitment phase by a committee from the Society for Cardiovascular Angiography and Interventions as an "identical definition of myocardial infarction for both PCI and CABG to minimize ascertainment bias and…that is clinically relevant." 9, 16 However, the Society for Cardiovascular Angiography and Interventions periprocedural MI definition was not aligned with both the Second and Third Universal Definitions of MI (Table 2) , is the only definition with an exclusively biochemical (ie, without ancillary clinical criterion) threshold for PCI and CABG, favored the use of creatine kinase-MB over cardiac troponin, and ultimately proved entirely different from the recently published Fourth Universal Definition of MI. 21 The results of trials comparing PCI and CABG that have periprocedural MI as a part of their composite primary end point are very sensitive to its definition, because it crucially affects the quantification of outcomes. In a study by Cho Figure 1 ).
Hence, a change in the definition of periprocedural MI, from the original EXCEL trial protocol contemporary with the Second Universal Definition to the Society for Cardiovascular Angiography and Interventions definition used for the analyses, affected the composite primary end point and the noninferiority result of the EXCEL study (Figure 2 ). Without this modification, it is plausible that the composite primary end point of major adverse cardiovascular events, which included periprocedural MI in the first 30 days, would have changed in favor of CABG, as evidenced by the 30-day to 3-year landmark analysis found in Table S9 of the Supplementary Appendix to the New England Journal of Medicine article. 9 Notably, nonfatal outcomes were "reset" at 30 days after the procedure for this landmark analysis, so patients were eligible to suffer another incidence of MI from 30 days on. Nonetheless, only 3 patients in the CABG group who had a periprocedural MI experienced another nonfatal MI, and subsequent MIs were much less frequent in the CABG group than in the PCI group. Although higher myocardial enzyme release at CABG can relate to less complete revascularization, itself linked to higher baseline risk and a diminished potential for late survival (through confounding by indication), 1 it does not appear that the "excess periprocedural MIs" 9 in the CABG group of the EXCEL trial were causally linked to repeat nonfatal MI, clinically evident loss of graft patency, or significant myocardium at risk.
In addition to the major variability between studies described above, the results of biochemical assays used for myocardial enzyme release differ widely from one laboratory to another, resulting in important withinstudy differences. The Fourth Universal Definition indicated that "one cannot presume that values from one 21 Taken together, there is no robust, consensual, mechanistic, or scientific evidence as to which exact biochemical cutoff value should be used to define periprocedural MI after PCI or CABG. We consequently recommend that periprocedural MI defined by enzyme release thresholds not be used as a component of the primary end point in trials comparing PCI and CABG because of its arbitrary and variable nature between studies, in addition to its relative imprecision within studies.
In terms of the end point of stroke, no excess signal was observed in the CABG groups of NOBLE and EXCEL. This is encouraging news for patients with LM or multivessel CAD worldwide because the incidence of perioperative stroke after CABG appears to have been significantly reduced, as corroborated by recent population data. 23 Previously, the increased incidence of stroke after CABG noted in the SYNTAX trial and the FREEDOM trial (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease) could have resulted from misguided pharmacological strategies such as prematurely stopping dual antiplatelet therapy in patients with acute coronary syndrome before CABG, 24 the low use of in situ arterial grafts, major geographic variations, 25 and the low use of no-touch aortic techniques. 26 Last, randomized and observational data indicate that guideline-directed medical therapy (GDMT) has been underused in patients receiving CABG, including those enrolled in PCI versus CABG trials, despite strong evidence that GDMT markedly improves outcomes. 27, 28 With the notable exception of the EXCEL trial, in which important efforts were accomplished to that end, CABG patients received markedly inferior GDMT in nearly every RCT that compared PCI with CABG, which inherently may have led to suboptimal clinical outcomes in the CABG group.
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SHORT-TERM FOLLOW-UP, SUBGROUP ANALYSES, AND THE POOLING OF SUBCOMPONENTS FROM COMPOSITE END POINTS: "NOT OBSERVING A DIFFERENCE" IS NOT THE SAME AS "SHOWING NO DIFFERENCE"
Clinical trials, whether positive, neutral, or negative, generate data for meta-analyses. Although patient data and studies brought together in a meta-analysis virtually always differ in their baseline, enrollment, and some of their therapeutic characteristics, other issues also can arise. For instance, the pooling of data from RCTs conducted in relatively young patients with short follow-up 
and EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization)
9 at 5 and 3 years of follow-up, respectively. A new periprocedural MI definition was used in EXCEL, and the 2 studies differed in their inclusion of periprocedural MI in the composite primary end point, resulting in early outcome differences (circles) in EXCEL but not in NOBLE. Outside of the periprocedural period, the slopes of event rates within the percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) groups across both studies appear remarkably similar. NOBLE reported that PCI was inferior to CABG at 5 years, whereas EXCEL indicated that PCI was noninferior to CABG at 3 years. and the performance of subgroup analyses using individual subcomponents of composite end points (such as all-cause mortality) can lead to underpowered or methodologically incorrect analyses, even with an apparently sizable number of patients at inception. 13, 30 Patients in their early 60s with few health issues and with good left ventricular function, who represent the typical population randomized in trials comparing PCI and CABG, may enjoy an average of 2 decades of additional life expectancy, according to US life tables. Death should not frequently occur in such study patients who have a low incidence of comorbidities, are treated for their LM or multivessel CAD, and are receiving GDMT with close follow-up. Consequently, a numerically increased hazard for death over a follow-up window of <4 years in patients who are in their early 60s (subdefined by the presence of diabetes mellitus or by SYNTAX score) may not reach statistical significance. 10 However, over the patients' average potential life span of ≈20 additional years, a numerically increased hazard can harbor profoundly negative impacts on late survival. In such patients, short-and medium-term mortality data should therefore be considered premature for the purpose of making comparisons between PCI and CABG.
Methodologically, both a priori prespecification and a value of P<0.05 on the test for interaction (after accounting for repeat testing) are required to provide convincing evidence for the validity of subgroup analyses in RCTs and in meta-analyses. 31 The recent meta-analysis by Head and colleagues, 10 which concluded that "the mortality benefit of CABG over PCI was seen only in patients with multivessel disease and diabetes," did so without providing evidence of multiple testing-adjusted, positive interaction tests. Furthermore, the subgroup analyses were markedly underpowered, with the width of the CI for the LM disease subgroup including not only the point of no difference but also the beneficial survival effects of CABG estimated in all patients, as well as in the multivessel CAD subgroup. Interpreting these data as showing no difference between modalities in the LM disease subgroup amounts to incorrect subgroup analysis practices and introduces the risk of potentially being generalized, affecting not only the interpretation of study results but, more important, future patient outcomes.
Last, pooling individual components of composite end points across patient subgroups also incorporates heterogeneity between trials, which cannot be accounted for in a post hoc manner. Should the conclusions of FREEDOM, 32 a trial performed exclusively in diabetic patients that found increased mortality with PCI regardless of SYNTAX score, be invalidated by the pooling of scattered diabetic patients from smaller trials followed up over shorter periods of time? 10 As per the earlier discussion, the question arises again: Who are the diabetic patients in the smaller, nondedicated trials, those carefully identified as likely to respond well to PCI? Overall, we must remember that the failure to observe a difference between groups is not the same as showing no difference.
QUALITY OF LIFE, QUANTITY OF LIFE, AND THE POSSIBLE IMPACT OF TARGET VESSEL REVASCULARIZATION
In 2017, it was reported that patients randomized to the PCI group in the EXCEL trial had 1-year quality of life and freedom from angina that were equivalent to those of the patients in the CABG group. 33 This was in contrast to prior observations from the SYNTAX and FREEDOM trials, in which quality of life scores were significantly better with CABG than with PCI 1 year after revascularization. 34, 35 In the EXCEL trial, nearly twice as many ischemia-driven revascularization events were noted in the PCI group (P<0.001). In this regard, any patient with known LM CAD who has persistent or recurrent angina is unlikely to be left untreated, even more so in the context of a research study, because of the well-known life-threatening consequences. Whether these revascularization events become positively or negatively perceived by the patient may depend in part on the research team, because these encounters constitute an additional opportunity for the team to interact with the patient. Attentive team dynamics in revascularization episodes, which were markedly more common with PCI, might have helped level a perception of different quality of life and overall functioning between patients with PCI and those with CABG. 36 More important, we believe that quality-of-life equivalence should be claimed only once quantity-oflife equivalence has been well established. The slopes of the major adverse cardiovascular event curves at 3 years in the EXCEL trial suggest that the PCI group could become significantly worse than the CABG group at years 4 and 5. Similarly, the landmark analysis of this trial (from 30 days to 3 years after revascularization) shows significantly more events and a numerical increase in the incidence of death in the PCI group. Previous trials such as FREEDOM have indicated that differences in all-cause mortality may take 2 to 3 years to develop between PCI and CABG patient groups (Figure 3 ). Although the EXCEL authors report that excess deaths in the PCI arm were noncardiovascular in origin, they rightly recognize that adjudication processes can be subject to ascertainment and misclassification biases. 9 A preliminary report of extended follow-up from the EXCEL trial indicates that a statistically significant mortality excess has emerged in the PCI arm, compared with the CABG arm, at 4 years of follow-up (10.3% versus 7.4%, respectively, P=0.04). However, the trial's events adjudication processes suggest that this relates mostly to noncardiovascular causes. 37 These results
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CONCLUSIONS
From the above considerations pertaining to trials that compare PCI and CABG for the treatment of LM and multivessel CAD, we recommend the following:
• Public funding should be made available and used to design, oversee, and execute myocardial revascularization trials.
• Methods articles of RCTs should be published early, ideally before trials have made significant strides in patient enrollment. Although updates on www. clinicaltrials.gov are practical, they also should highlight the first approved version of each protocol, including original target recruitment numbers and end point definitions.
• Rather than the design and pooling of data from trials with short follow-up duration, only trials with ≥5 years of follow-up should be considered to comparatively evaluate outcomes after myocardial revascularization.
• A common set of definitions for outcomes and complications such as the VARC-2 (Valve Academic Research Consortium-2) criteria in the transcatheter aortic valve implantation literature should serve as a common basis for the designing and reporting of outcomes of myocardial revascularization trials. Such a process would include balanced authorship representation, coleadership from the key specialties, review by a predefined and accountable expert committee, and wide stakeholder acceptance.
• Outcomes of an arbitrary nature and prone to considerable variability between trials and within trials such as periprocedural myocardial enzyme release assay thresholds should not be used as components of the primary end point in RCTs that compare PCI and CABG.
• Revascularization guidelines should not be changed on the basis of the EXCEL trial and the recent meta-analysis by Head and colleagues 10 until meaningful follow-ups are completed and analyzed using primary end point components that are not arbitrarily defined or subject to modification during the course of the trial, as well as adequately powered, methodologically justified noninferiority boundaries and subgroup analyses.
• If myocardial revascularization trials have randomized primarily patients likely to do as well with PCI as with CABG, with most of the screened patients not having been randomized and having majoritarily undergone CABG instead, then the conclusions of these trials and the guidelines stemming from them should not be applied to the entire population of patients with severe CAD.
• The development of guidelines should follow the methodology suggested by the Institute of Medicine, 38 with an independent epidemiology/ statistician group appraising the evidence and detecting statistical flaws and a separate group made of physicians writing the recommendations on the basis of the synthesized evidence and its independent critical analysis. 39 • Data from myocardial revascularization RCTs should better focus on the anatomic characteristics of LM lesions to ascertain who the patients with LM CAD are who may fare as well with PCI as with CABG.
• Until more evidence is available, except for ostial or midshaft isolated LM disease or LM disease associated with 1-vessel disease, all decisions for stable multivessel, LM with 2-or 3-vessel disease, or LM with bifurcation CAD should be discussed with the patient after review and recommendation by a heart team, which includes a cardiac surgeon.
• Patients undergoing CABG should be offered the best and latest in terms of adjunctive GDMT, not only within the context of myocardial revascularization trials but also, and more important, because they represent such a large population of patients with severe CAD who crucially can benefit from GMDT.
• Cardiologists and cardiac surgeons must work closely together in true collaborative fashion and with balanced leadership opportunities to advance the optimal clinical care and research aimed at improving the current and future status of patients with severe CAD. 
